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Introduction: Determining the presence or absence of red blood cells (RBC) or their breakdown 
products in cerebrospinal fluid (CSF) is essential for the evaluation of subarachnoid hemorrhage 
(SAH) in headache patients. Current methodology for finding blood in the CSF is either 
spectrophotometric detection of pigment, which is time consuming and labor intensive, or visual 
assesment of samples for color change (xanthochromia), which is inaccurate. Bayer Multistix® 
urine test strips are designed to test urine for RBC by detecting the presence of hemoglobin. The 
aim of this pilot study was to evaluate the perfomance of urine reagent test strips for ruling out the 
presence of RBC in CSF. 
Methods: We compared color changes on Multistix® urine test strips to the standard of 
spectrophotometric absorbtion at 415nm and initial RBC counts in 138 visually clear CSF samples. 
Results: We performed Pearson Chi-Square and likelihood ratios on the results and found a 
correlation between a negative result on the urine test strip and less than 5 RBC per high power field 
and a spectrophotometric absorbance of less than 0.02% at 415nm in a CSF sample. 
Conclusion: These results warrant further investigation in the form of a prospective clinical 
validation as it may alter the emergency department evaluation for SAH. [West J Emerg Med. 
2011;12(1):63-66.]
INTRODUCTION
Patients presenting to the emergency department 
complaining of rapid onset or “thunderclap” headache require 
an urgent clinical evaluation to rule out a subarachnoid 
hemorrhage (SAH). This process typically involves a non-
contrast head computed tomography and, if negative, a lumbar 
puncture to determine the presence of blood or blood products 
in the cerebrospinal fluid (CSF). The characteristic, faint 
yellow staining of CSF by RBC breakdown products is known 
as xanthochromia. When red blood cells (RBC) lyse in CSF 
they release hemoglobin that is later enzymatically converted 
to methemoglobin and bilirubin. The number of intact blood 
cells is typically determined by either an automated cell 
counter or by counting cells per high power field in manual 
microscopy. Most United States laboratories currently 
determine xanthochromia by using a visual testing method in 
which a sample of CSF is compared to a white background 
and any staining present is noted. Unfortunately results can be 
highly inaccurate if the visual testing method is employed.1 
The more accurate but less common method for determining 
xanthochromia is to use a spectrophotometer and record a 
sample absorbance at wavelengths known to correspond with 
breakdown pigments, such as hemoglobin, methemoglobin 
and bilirubin. Laboratory evaluation of CSF can require one to 
two hours or more to complete if spectrophotometric methods 
are used. Quickly and reliably confirming the lack of clinically 
significant levels of RBC in CSF might significantly expedite 
the evaluation of these headache patients. When evaluating a 
patient for the possibility of SAH a negative reagent test for 
blood might obviate further lab investigation or imaging. A 
straightforward, rapid reagent test has the potential to save 
clinical time and diagnostic costs.
Other medical settings in which reliable, expeditious 
CSF results would be valuable are those with less access to Western Journal of Emergency Medicine  64  Volume XII, no. 1  :  February 2011
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technology and resources. Across Third World nations and 
in military Combat Support Hospitals, patients requiring 
evaluations for headaches may not have access to radiology, 
photo spectrometry, microscopy or automated cell counters. 
In these austere settings, visually ruling out xanthrochromia 
becomes paramount. A reagent test that capitalizes on 
simplicity and economy would better serve these resource-
constrained facilities. 
METHODS
Research data were derived as an approved study under 
the supervision of the local Institutional Review Board/
Institutional Animal Care and Use Committee protocol (CIP# 
2006.0027). We conducted a laboratory evaluation from July 
to October 2006, using CSF samples submitted to the 
hospital laboratory. In the vast majority of cases the volume 
of CSF submitted to a lab is more than is needed for the 
requested diagnostic evaluation. This study intercepted this 
surplus CSF prior to disposal. The CSF was stored for up to 
one week at 4°C until analyzed, then allowed to warm to 
room temperature prior to testing. We inspected all samples 
to eliminate those with any visually discernible 
xanthochromia. This visual sorting was undertaken to narrow 
our test pool only to samples that would have been classified 
as negative using the common practice methods in place in 
most labs. A visually pigmented sample needs no further 
evaluation as it is already positive. The investigators found 
138 samples to be visually clear. 
We placed each clear sample placed in a Bausch & 
LombTM Spectronic 601 spectrophotometer and recorded the 
percent light absorption at 415 nm. Xanthochromia is 
considered present in CSF when spectrophotometric 
absorbance >0.024% at 415nm. Graves et al2 has recently 
suggested a more conservative value of >0.023%. We used a 
cutoff of >0.02% at 415nm to provide a safety margin and to 
reflect the trend toward a more stringent threshold for 
xanthochromia. 
A different investigator used a Bayer Multistix® urine test 
strip to test the same sample for the presence of blood. 
Following the manufacturer’s procedure for urine testing, we 
placed a drop of sample CSF on the blood square on the urine 
test strip. At 60 seconds, we noted and compared the color 
change against the key found on the side of the container. 
Since the CSF used in this study were samples that had 
already been analyzed by the hospital lab, at the end of each 
testing session we looked up and recorded each sample’s cell 
counts after visual sorting, spectrophotometry and urine test 
strip analysis was completed. We then compared the urine 
dipstick testing results to the CSF blood cell counts and 
spectrophotometric results for statistical analysis. 
We maintained a pooled sample of CSF known to be free 
of red cells and tested it biweekly with urine strips to ensure 
that the test strips would not yield false positive results due to 
aging CSF or other unanticipated factors. This true negative 
standard was made from CSF samples that had shown no 
absorbance on spectrophotometry, had tested negative on 
the test strips, and did not contain greater than five red cells 
per high power field. We used this standard as a measure to 
ensure that true negative results on the test strips were reliable, 
reproducible, and durable.
RESULTS
Since the goal of this project was to use urine test strips to 
rule out the presence of red cells in CSF, we distributed the 
results into two groups. Group one consisted of samples with 
negative urine dip results. Group two was comprised of 
samples showing any positive dip result. We considered a 
sample positive if there was any color change on the test strip, 
regardless of the magnitude or pattern of the color change. 
Sixty-three of 138 samples tested negative for blood using the 
urine dipstick method.
We assigned spectrophotometer results above the cutoff to 
one group, below to a second. Using spectrophotometric 
methods, we found that 103 of 138 samples tested negative for 
xanthochromia. 
The microscopic analysis results for RBCs per high power 
field were assigned to one of three groups: 0-5, 6-10, and >10. 
We chose two cutoffs for red blood cells (5/hpf and 10/hpf) to 
represent common lab thresholds for “normal” red cells in 
CSF. Ninety-nine samples had <5 rbc/hpf, 12 samples had 
5-10 rbc/hpf, and 27 samples were >10 rbc/hpf. The Multistix® 
proved to be very sensitive. Of samples with zero to five cells 
per high power field, 37 showed some positive results. When a 
threshold of zero cells per high power field was used, 15 out 
of 138 samples were false positive.
We conducted two Pearson Chi-Square tests. The first 
compared samples above and below the spectrophotometric 
Table 1. Absorbance at 415nm.
Absorbance at 415nm
>= 0.021 < 0.020 Total
Multistix® Result positive 32 43 75
negative 3 60 63
Total 35 103 138
Table 2. Red blood cells per high power field.
Red blood cells per high power 
field
>10 5-10 0-5 Total
Multistix® Result positive 26 12 37 75
negative 1 0 62 63
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cutoff to samples with negative and non-negative results on 
the urine test strips (Table 1). The second compared the three 
sets of red cell results to negative and non-negative results on 
the urine test strips (Table 2). We found significant correlation 
(p<0.0001) between a negative result on the urine test strip 
and the negative cutoff of 0.020% spectrophotometric 
absorption at 415nm. We found this same correlation 
(P<0.0001) between a negative test strip result and a CSF 
microscopic reading <5 RBC/HPF. Tables 3 and 4 depict the 
statistical results. 
When compared to spectrophotometry, the Multistix® had 
a sensitivity of 0.91 and a negative predictive value of 0.95, 
with a specificity of only 0.58. The negative likelihood ratio 
was 0.16. When compared to the RBC/HPF (cutoff of <5), the 
Multistix® had a sensitivity of 0.97, a negative predictive 
value of 0.98, with a specificity of 0.62. The negative 
likelihood ratio was 0.04. We used the highly conservative 
spectrophotometric cutoff value of 0.020 for this analysis; 
only further work will determine if this cutoff was too 
conservative. 
The true negative pooled CSF yielded no false positive 
reaction on the Multistix® during the four-month period of this 
study.
DISCUSSION
A SAH occurs with the release of blood into the CSF. It 
subsequently breaks down over time into the characteristic 
pigments of hemoglobin, bilirubin and methhemoglobin. 
Hemoglobin from red cell lysis is the first significant 
compound, presenting as early as two hours, peaking at 
around 24 hours, and persisting for up to a week. Bilirubin is 
only created in vivo and much later than hemoglobin, as its 
creation requires the action of an arachnoid oxygenase not 
present in the test tube once a sample is collected, making it 
much more difficult to study. Methemoglobin represents 
another RBC breakdown product that, like bilirubin, is only 
encountered after time. Typically patients with severe 
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headaches present acutely, often within a few hours of onset of 
their symptoms. This makes hemoglobin the best target 
pigment for this pilot work in test strip diagnosis of blood in 
the CSF. As Multistix® include a Bilirubin test block, 
subsequent clinical exploration should include this pigment. 
We were concerned about the number of samples that 
were visually pigment free, per the inclusion criteria for this 
study, but which subsequent microscopic or 
spectrophotometric analysis indicated were positive for blood. 
These findings support other authors’1, 3, 4 misgivings about 
using visually determined xanthochromic absence to rule out 
intrathecal blood. Unfortunately, testing for xanthochromia 
using visual methodology is still employed by many hospitals, 
particularly in the United States. Should urine test strip results 
correlate well with spectrophotometric results, they would 
provide for a quick, easy alternative to visual xanthochromia 
determination in centers without access to spectrophotometery. 
An examination of the data reveals almost two thirds of 
the visually clear samples tested negative for blood via 
reagent strips. Hence the statistical reassignment was 
undertaken. Our goal was to evaluate the performance of the 
Multistix® in a Boolean, yes/no paradigm. In other words, we 
wanted to know how good a negative result on the Multistix® 
was. When compared to the gold standard of 
spectrophotometery for xanthochromia, the Multistix® 
showed promise as a simple test to rule out red cells in the 
CSF. SAH is a life-threatening condition. High test 
sensitivity is essential in a screening test for detecting of 
intrathecal blood. With a high sensitivity a resultant increase 
in false positive results is to be expected. The false positive 
rate would need to be closely monitored if this diagnostic 
method were to be evaluated in a clinical setting. It may 
subsequently be shown that CSF testing with urine test strips 
is only useful when the result is negative.
As the focus of this study was a bench-top evaluation of 
the performance of urine test strips in analyzing CSF, the 
circumstances and settings under which we obtained these 
samples were of secondary importance. Often novel diagnostic 
strategies are evaluated directly in a clinical setting without 
first determining whether they perform in a controlled 
laboratory setting. 
Our use of an all comers convenience sample implies 
that some of the CSF we analyzed was obtained from patients 
in whom other diagnoses, such as infection rather than 
subarachnoid hemorrhage, were being entertained. Might 
there be some protein or entity present during an infection 
and not present during simple hemorrhage that would yield 
a false positive result? Bayer assured the investigators that 
the “heme” portion of the Multistix® was specific for blood. 
Unfortunately the exact mechanism of the colorimetric 
reaction is understandably proprietary. Multistix® detect 
hemoglobin in the cell; therefore, it can be inferred that the 
process of spotting samples onto urine reagent strips lyses 
Table 4. Red blood cells per high power field vs. Multistix®
Red blood cells per high power field vs. 
Multistix®
Value Asymp Sig (p-value)
Pearson Chi-Square 40.726 0.000
Table 3. Absorbance vs. Multistix®
Absorbance vs. Multistix®
Value Asymp Sig (p-value)
Pearson Chi-Square 25.987 0.000
Continuity Correction (2x2) 24.024 0.000Western Journal of Emergency Medicine  66  Volume XII, no. 1  :  February 2011
red cells to release their contents for subsequent detection by 
colorimetric chemical reaction. This lysis effectively removes 
the potential confound of early tap analyzed prior to cell lysis 
and release of pigment. 
LIMITATIONS
This is a relatively small, bench-top pilot study; no 
clinical implications are suggested or warranted without 
proper prospective validation. 
Traumatic tap rates are reported as high as 10%.3 As urine 
test strips most likely lyse cells in their detection of pigment, 
they would be unlikely to assist with detecting a traumatic tap 
caused by the presence of hemoglobin. Bilirubin theoretically 
shows more promise for differentiating traumatic lumbar 
puncture from subarachnoid hemorrhage, with the important 
caveat that it would only be expected to be present at 12 hours 
after the onset of bleeding.4 As this study used lab surplus CSF 
samples of varying ages, we did not assess the performance of 
the Bilirubin panel on the urine test strips. 
The use of surplus samples made it impossible to control 
for the clinical setting of the lumbar puncture. These samples 
left us unable to ascertain the indications for the procedure 
or the technique employed to obtain the samples. Some 
authors have suggested that using Betadine® as a skin prep can 
introduce spurious coloration to a sample.5 While it is unlikely 
that storage of CSF affected the results, this study’s use of 
lab samples represents a potential confound that can only be 
addressed by a clinical trail.
CONCLUSION
Given a correlation between a negative result on the urine 
test strip and less than five RBC per high power field and a 
spectrophotometric absorbance of less than 0.02% at 415nm 
in a CSF sample, determining the absence of CSF RBCs via 
benchtop CSF evaluation of urine test strips shows enough 
promise to warrant further study in a prospective clinical 
setting. Ultimately this may prove to be an expeditious and 
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cost-effective adjunct to the evaluation of headaches when 
ruling out subarachnoid hemorrhage.
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